4d Molecular Therapeutics Stock Fundamentals
| FDMT Stock | USD 4.58 0.10 2.14% |
4D Molecular Therapeutics fundamentals help investors to digest information that contributes to 4D Molecular's financial success or failures. It also enables traders to predict the movement of FDMT Stock. The fundamental analysis module provides a way to measure 4D Molecular's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to 4D Molecular stock.
At this time, 4D Molecular's Net Interest Income is comparatively stable compared to the past year. Interest Income is likely to gain to about 11.1 M in 2025, whereas Total Revenue is likely to drop slightly above 12.9 M in 2025. FDMT | Select Account or Indicator |
4D Molecular Therapeutics Company Current Valuation Analysis
4D Molecular's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current 4D Molecular Current Valuation | (265.34 M) |
Most of 4D Molecular's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, 4D Molecular Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
FDMT Current Valuation Historical Pattern
Today, most investors in 4D Molecular Stock are looking for potential investment opportunities by analyzing not only static indicators but also various 4D Molecular's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of 4D Molecular current valuation as a starting point in their analysis.
4D Molecular Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, 4D Molecular Therapeutics has a Current Valuation of (265.34 Million). This is 101.85% lower than that of the Biotechnology sector and 105.71% lower than that of the Health Care industry. The current valuation for all United States stocks is 101.6% higher than that of the company.
4D Molecular Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining 4D Molecular's current stock value. Our valuation model uses many indicators to compare 4D Molecular value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across 4D Molecular competition to find correlations between indicators driving 4D Molecular's intrinsic value. More Info.4D Molecular Therapeutics is one of the top stocks in return on equity category among its peers. It is rated # 2 in return on asset category among its peers . At this time, 4D Molecular's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value 4D Molecular by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.FDMT Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 4D Molecular's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of 4D Molecular could also be used in its relative valuation, which is a method of valuing 4D Molecular by comparing valuation metrics of similar companies.4D Molecular is currently under evaluation in current valuation category among its peers.
4D Molecular ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, 4D Molecular's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to 4D Molecular's managers, analysts, and investors.Environmental | Governance | Social |
FDMT Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.17 | ||||
| Current Valuation | (265.34 M) | ||||
| Shares Outstanding | 46.23 M | ||||
| Shares Owned By Insiders | 3.91 % | ||||
| Shares Owned By Institutions | 96.09 % | ||||
| Number Of Shares Shorted | 7.99 M | ||||
| Price To Book | 0.38 X | ||||
| Price To Sales | 12,726 X | ||||
| Revenue | 20.72 M | ||||
| Gross Profit | (97.08 M) | ||||
| EBITDA | (107.12 M) | ||||
| Net Income | (100.84 M) | ||||
| Cash And Equivalents | 241.09 M | ||||
| Cash Per Share | 7.45 X | ||||
| Total Debt | 14.67 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 17.20 X | ||||
| Book Value Per Share | 7.15 X | ||||
| Cash Flow From Operations | (75.79 M) | ||||
| Short Ratio | 7.94 X | ||||
| Earnings Per Share | (2.79) X | ||||
| Price To Earnings To Growth | (0.07) X | ||||
| Target Price | 37.91 | ||||
| Number Of Employees | 147 | ||||
| Beta | 2.8 | ||||
| Market Capitalization | 216.35 M | ||||
| Total Asset | 339.89 M | ||||
| Retained Earnings | (415.33 M) | ||||
| Working Capital | 277.64 M | ||||
| Net Asset | 339.89 M |
About 4D Molecular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 4D Molecular Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 4D Molecular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 4D Molecular Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 245.7 K | 233.4 K | |
| Total Revenue | 23.8 M | 12.9 M | |
| Cost Of Revenue | 111.7 M | 117.2 M | |
| Stock Based Compensation To Revenue | 0.85 | 0.94 | |
| Sales General And Administrative To Revenue | 1.58 | 2.07 | |
| Research And Ddevelopement To Revenue | 4.22 | 5.35 | |
| Capex To Revenue | 0.12 | 0.11 | |
| Revenue Per Share | 0.61 | 0.56 | |
| Ebit Per Revenue | (6.26) | (6.58) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.